Glooko, a US-based diabetes patient monitoring system developer backed by consumer electronics producer Samsung, merged with Sweden-based diabetes data management platform Diasend on Tuesday.
Venture capital firm Canaan Partners led a $8m funding round for the merged company alongside the deal, with participation from Samsung’s corporate venturing arm, Samsung Ventures, Social Capital and Glooko founder Yogen Dalal.
Glooko operates a mobile cloud-based platform that allows healthcare providers to remotely engage with diabetes patients, who can track their glucose level through a Bluetooth-enabled device and app.
Diasend has created a data management platform that collects, stores and analyses data from more than 140 different glucose meters, insulin pumps, activity trackers and continuous glucose monitoring systems.
The joint platform will operate as Glooko and serve a total of 4,000 diabetes clinics in 23 countries. The new company claims its products are compatible with more than 95% of diabetes devices used across the world.
Diasend has not disclosed any previous funding. Glooko raised $16.5m in a March 2015 series B round featuring Samsung, medical device maker Medtronic, Canaan and Social Capital.
Samsung also supported a $10.5m series A round, closed in 2014, which included Social Capital, Lifeforce Ventures, Xtreme Labs and assorted angel investors. Social Capital, Xtreme and individual investors provided $1m in seed capital for Glooko in 2010.